» Articles » PMID: 29043133

Lysozyme Amyloidosis - a Case Report and Review of the Literature

Overview
Specialty Nephrology
Date 2017 Oct 19
PMID 29043133
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Lysozyme amyloidosis is an exceedingly rare hereditary autosomal dominant amyloidosis, which is characterized by the precipitation of lysozyme protein within the body, leading to multi-organ dysfunction. Herein, we present the case of a U.S. family affected by lysozyme amyloidosis. In particular, we report pericardial disease involvement leading to recurrent pericardial effusion, which to our knowledge has not been described yet. To our knowledge, we have also for the first time identified the amyloidogenic component of lysozyme amyloidosis via laser microdissection and mass spectrometry from a bone marrow biopsy. The diagnosis of this disease remains challenging as it can be easily mistaken for primary amyloidosis, which also presents with similar symptoms. Immunohistochemical staining of tissue for specific amyloidogenic proteins allows for an accurate diagnosis and should be performed in all amyloidosis patients in order to spare patients from potentially futile or harmful therapy. The widespread systemic involvement of lysozyme amyloidosis currently provides limited options for treatment, although kidney and/or liver transplantation appear to be promising palliative treatments. Practicing clinicians and researchers need to collect more information about this rare entity to further characterize the behavior of this disease and develop new potential treatment strategies.

Citing Articles

Cathepsin B prevents cell death by fragmentation and destruction of pathological amyloid fibrils.

Sulatsky M, Stepanenko O, Stepanenko O, Mikhailova E, Sulatskaya A Cell Death Discov. 2025; 11(1):61.

PMID: 39955315 PMC: 11830053. DOI: 10.1038/s41420-025-02343-w.


The inhibition of fibril formation of lysozyme by sucrose and trehalose.

Ahlgren K, Havemeister F, Andersson J, Esbjorner E, Swenson J RSC Adv. 2024; 14(17):11921-11931.

PMID: 38623289 PMC: 11017192. DOI: 10.1039/d4ra01171f.


Investigating lysozyme amyloid fibril formation and structural variability dependence on its initial folding state under different pH conditions.

Ziaunys M, Mikalauskaite K, Sakalauskas A, Smirnovas V Protein Sci. 2023; 33(2):e4888.

PMID: 38151910 PMC: 10804668. DOI: 10.1002/pro.4888.


Secondary structure and toxicity of lysozyme fibrils are determined by the length and unsaturation of phosphatidic acid.

Ali A, Zhaliazka K, Holman A, Kurouski D Proteins. 2023; 92(3):411-417.

PMID: 37909765 PMC: 11075103. DOI: 10.1002/prot.26622.


Kidney Biopsy Corner: Amyloidosis.

Biederman L, Dasgupta A, Dreyfus D, Nadasdy T, Satoskar A, Brodsky S Glomerular Dis. 2023; 3(1):165-177.

PMID: 37901698 PMC: 10601942. DOI: 10.1159/000533195.


References
1.
Pinney J, Lachmann H, Sattianayagam P, Gibbs S, Wechalekar A, Venner C . Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant. 2012; 13(2):433-41. DOI: 10.1111/j.1600-6143.2012.04326.x. View

2.
Lachmann H, Booth D, Booth S, Bybee A, Gilbertson J, Gillmore J . Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346(23):1786-91. DOI: 10.1056/NEJMoa013354. View

3.
Hawkins P, Aprile C, Capri G, Vigano L, Munzone E, Gianni L . Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med. 1998; 25(7):701-8. DOI: 10.1007/s002590050272. View

4.
Sucker C, Hetzel G, Grabensee B, Stockschlaeder M, Scharf R . Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006; 47(6):947-55. DOI: 10.1053/j.ajkd.2006.03.036. View

5.
Harrison R, Hawkins P, Roche W, MacMahon R, Hubscher S, Buckels J . 'Fragile' liver and massive hepatic haemorrhage due to hereditary amyloidosis. Gut. 1996; 38(1):151-2. PMC: 1382995. DOI: 10.1136/gut.38.1.151. View